Endo Pharma Agrees to Pull Abuse-Deterrent Opioid Endo Pharma Agrees to Pull Abuse-Deterrent Opioid

Following a June request by the FDA, the company will pull its abuse-deterrent extended-release formulation of oxymorphone (Opana ER) from the market.News Alerts
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Psychiatry News Alert Source Type: news